Investor Relations & Capital Introduction in Ghent

Ghent is one of Europe's leading biotechnology hubs and a major Flemish port and university city. For founders in life sciences, agricultural biotechnology and industrial technology, it offers world-class research and experienced specialist investors.

Why Ghent Matters for Capital Raising

The Flanders Institute for Biotechnology, VIB, was founded in 1996 and is headquartered in Ghent, supporting a strong pipeline of biotech spinouts.

Ghent University, founded in 1817, is one of Belgium's largest research universities, and the region has produced notable biotechnology companies.

North Sea Port, formed in 2018, links Ghent with Dutch ports and supports industry and logistics.

What Ghent Investors Examine

Scientific data, intellectual property and clinical or regulatory pathway are examined in detail.

Investors look for experienced leadership and international partnerships.

The Ghent Startup and Investor Ecosystem

Ghent's innovation activity is concentrated in the Technologiepark in Zwijnaarde, on the southern edge of the city, where university laboratories, incubator space and research-driven companies sit side by side. The listed biotechnology group argenx is headquartered in the Ghent area, and the city's bioincubator gives young life sciences companies access to laboratories and shared equipment.

Ghent University's technology transfer office and its university-linked funds support spinouts in biotechnology, engineering and digital technology, while HOGENT and Artevelde University of Applied Sciences supply practical skills to regional employers. Industry remains important, with Volvo Car Gent and the ArcelorMittal steelworks along the canal zone among the largest employers. Founders in Ghent often raise early rounds from Flemish specialist funds before turning to Brussels, Amsterdam and international life sciences investors for later-stage capital.

Investor Types Active in Ghent

Ghent's investor community includes specialist life sciences venture funds, university-linked seed funds and Flemish regional investment companies, alongside family offices built on the region's industrial and agricultural businesses. Corporate venture arms of pharmaceutical and agrifood groups invest strategically, and international biotechnology investors frequently lead later rounds. These investors value rigorous science, defensible intellectual property, experienced clinical teams and a credible route to partnership or exit.

Engagement and Access

GCN connects founders with Ghent specialist life sciences funds, family offices and angel investors, alongside the Brussels investor community, through conference programming and private sessions.

Sectors where we see consistent Ghent interest include biotechnology, agricultural biotechnology, medical technology, industrial technology and logistics.

Partner with Global Capital Network

Whether you are raising into Ghent or allocating from it, our team can discuss how our investor relations infrastructure applies to your objectives.